MedTrace Logo

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01976338 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2017-05-08

Study results available
· View outcomes & findings →

Summary

Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO

Conditions

  • Macular Edema Secondary to Branch Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab 0.5 mg

intravitreal injection of 0.05 ml

OTHER

Sham injection

Sham intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-12
Primary Completion
2016-03-28
Completion
2016-03-28

Countries

  • China
  • Hong Kong
  • Indonesia
  • Philippines
  • Taiwan
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976338 on ClinicalTrials.gov